title: Pharmacological characterization of recombinant human and rat P2X receptor subtypes.
abstract: ATP functions as a fast neurotransmitter through the specific activation of a family of ligand-gated ion channels termed P2X receptors. In this report, six distinct recombinant P2X receptor subtypes were pharmacologically characterized in a heterologous expression system devoid of endogenous P2 receptor activity. cDNAs encoding four human P2X receptor subtypes (hP2X1, hP2X3, hP2X4, and hP2X7), and two rat P2X receptor subtypes (rP2X2 and rP2X3), were stably expressed in 1321N1 human astrocytoma cells. Furthermore, the rP2X2 and rP2X3 receptor subtypes were co-expressed in these same cells to form heteromultimeric receptors. Pharmacological profiles were determined for each receptor subtype, based on the activity of putative P2 ligands to stimulate Ca2+ influx. The observed potency and kinetics of each response was receptor subtype-specific and correlated with their respective electrophysiological properties. Each receptor subtype exhibited a distinct pharmacological profile, based on its respective sensitivity to nucleotide analogs, diadenosine polyphosphates and putative P2 receptor antagonists. Alphabeta-methylene ATP (alphabeta-meATP), a putative P2X receptor-selective agonist, was found to exhibit potent agonist activity only at the hP2X1, hP2X3 and rP2X3 receptor subtypes. Benzoylbenzoic ATP (BzATP, 2' and 3' mixed isomers), which has been reported to act as a P2X7 receptor-selective agonist, was least active at the rat and human P2X7 receptors, but was a potent (nM) agonist at hP2X1, rP2X3 and hP2X3 receptors. These data comprise a systematic examination of the functional pharmacology of P2X receptor activation.
authors.affiliation: Neurological and Urological Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064-3500, USA.
authors.forename: B R
authors.initials: BR
authors.lastname: Bianchi
authors.forename: K J
authors.initials: KJ
authors.lastname: Lynch
authors.forename: E
authors.initials: E
authors.lastname: Touma
authors.forename: W
authors.initials: W
authors.lastname: Niforatos
authors.forename: E C
authors.initials: EC
authors.lastname: Burgard
authors.forename: K M
authors.initials: KM
authors.lastname: Alexander
authors.forename: H S
authors.initials: HS
authors.lastname: Park
authors.forename: H
authors.initials: H
authors.lastname: Yu
authors.forename: R
authors.initials: R
authors.lastname: Metzger
authors.forename: E
authors.initials: E
authors.lastname: Kowaluk
authors.forename: M F
authors.initials: MF
authors.lastname: Jarvis
authors.forename: T
authors.initials: T
authors.lastname: van Biesen
mesh_terms: D000255:Adenosine Triphosphate / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000378:metabolism; D005453:Fluorescence; D006801:Humans; D007700:Kinetics; D009865:Oocytes; D018408:Patch-Clamp Techniques; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D051381:Rats; D018048:Receptors, Purinergic P2 / Q000096:biosynthesis / Q000502:physiology; D011994:Recombinant Proteins / Q000819:agonists / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D014162:Transfection; D014407:Tumor Cells, Cultured; D014981:Xenopus
chemical_list: D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D011994:Recombinant Proteins; D000255:Adenosine Triphosphate; D002118:Calcium